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Introduction
The dopamine-3 (D3) receptor subtype has been identified as
a major target for several agents currently in clinical use for
the treatment of schizophrenia, Parkinson’s disease, depres-
sion, and other neurological diseases.[1–3] Because all of the
clinically approved drugs target not only the D3 receptor, but
also have high affinities for the D2 receptor and have other off-
target effects,[4, 5] there is a need to design potent and selective
D3 ligands. Such new compounds can be used to further inves-
tigate the role of the D3 receptor in different biological and
pharmacological processes and to validate unambiguously the
D3 receptor as an important therapeutic target in preclinical
and clinical studies.
The design of potent and highly selective D3 ligands has
been a challenge for many years given the high degree of se-
quence homology between the D2 and D3 receptors and nearly
identical primary sequences that form their binding sites.[4, 5]
However, recent studies, including those from our research
group, have shown that it is possible to design highly selective
and potent D3 ligands.
[6–8] For example, based on pramipexole
(1), a potent D3 agonist with only a modest selectivity over the
D2 receptor, we have developed CJ-1368 (2) and CJ-1639 (3) as
potent and selective D3 agonists (Figure 1).
[8] More recently, we
reported the design of highly selective D3 antagonists based
on the structure of tranylcypromine.[9]
Both compounds 2 and 3 display a high affinity for the D3
receptor and excellent selectivity over the D2 and D1 receptors,
and are thus promising lead compounds. Toward the identifi-
cation of highly selective D3 agonists that can be used for in-
vestigations in vivo, we performed further evaluations of com-
pounds 2 and 3. It was found that these compounds have
moderate or poor human liver microsomal stability, a shortcom-
ing for their use in vivo. In the present study, we modified
these compounds with the objective of improving their meta-
bolic stability, as well as further enhancing their selectivity for
the D3 over the D2 receptor, while maintaining high affinity for
the D3 receptor.
Results and Discussion
Microsomal stability testing showed that compound 2 has a
t1/2 of 26 min and compound 3 has a t1/2 of 9.5 min in human
Herein we report the synthesis and evaluation of a series of
new pramipexole derivatives as highly potent and selective ag-
onists of the dopamine-3 (D3) receptor. A number of these
new compounds bind to the D3 receptor with sub-nanomolar
affinity and show excellent selectivity (>10000) for the D3 re-
ceptor over the D1 and D2 receptors. For example, compound
23 (N-(cis-3-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-(5-methyl-1,2,4-
oxadiazol-3-yl)benzamide) binds to the D3 receptor with a Ki
value of 0.53 nm and shows a selectivity of >20000 over the
D2 and D1 receptors in the binding assays using a rat brain
preparation. It has excellent stability in human liver micro-
somes. Moreover, in vitro functional assays showed it to be
a full agonist for the human D3 receptor.
Figure 1. Structures of pramipexole (1) and two potent and selective D3
agonists 2 and 3.
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liver microsomes (Table 1). To improve the metabolic stability
of the compounds, we analyzed the metabolites of compound
2 in human liver microsomes. Our results suggest that hydrox-
ylation of the electron-rich naphthalene group is the major
metabolic biotransformation in human liver microsomes
(Figure 2 and Supporting Information). Accordingly, in this
study we focused our modifications on the naphthalene
group. We hypothesized that replacement of the naphthyl
group in compound 2 with less electron-rich groups may im-
prove the metabolic stability and accordingly, a series of new
compounds (11–23) with groups less electron-rich than the
naphthyl group, such as unsubstituted or substituted phenyl
rings, were synthesized and evaluated.
These compounds were first evaluated for their binding af-
finities to the rat D1-like, D2-like, and D3 receptors using a rat
brain preparation (Table 2). Our binding data showed that all
compounds with a phenyl ring, substituted or unsubstituted,
have high affinities for the D3 receptor, with Ki values in the
range of 0.43–1.9 nm. Compound 11, which has a phenyl
group in place of the naphthyl group, binds to the D3 receptor
with a Ki value of 0.74 nm and is 301-fold more selective for
the D3 receptor over the D2 receptor. Chlorine substitution at
the ortho, meta, and para positions on the phenyl group re-
sulted in compounds 12, 13, and 14, respectively. These have
similar affinities for the D3 receptor and also similar selectivities
over the D2 receptor, as compound 11. Fluorine substitution at
the three different positions on the phenyl ring yielded com-
pounds 15–17. Whereas compounds 16 and 17, with a meta-
fluoro or a para-fluoro substituent, have similar affinities for
the D3 receptor and also similar selectivities over the D2 recep-
tor, as compound 11, compound 15 with the ortho-fluoro sub-
stituent, has high affinity for the D3 receptor and a selectivity
of >30000-fold over the D2 receptor. The m-chloro-p-fluoro
compound 18 also has high affinity for the D3 receptor (Ki=
0.43 nm) and outstanding selectivity (>15000-fold) over the D2
receptor. Methoxy group substitution at three different posi-
tions on the phenyl ring generated compounds 19–21, all of
which have similar binding affinities for the D3 receptor (0.70–
1.0 nm). The meta-methoxy compound 21 is >12000-fold se-
lective for D3 over the D2 receptor, the highest selectivity
among these three compounds. Hence, it appears that while
substitution on the phenyl ring has a modest effect on the af-
finity for the D3 receptor, it can have a major effect on the se-
lectivity for the D3 receptor over the D2 receptor.
In addition to these simple substituents, we also synthesized
compounds 22 and 23 containing a 5-methyl-1,2,4-oxadiazol-
3-yl substituent at the meta or para positions, respectively.
Compounds 22 and 23 bind to the D3 receptor with respective
Ki values of 0.96 and 0.53 nm, and both show very high selec-
tivities (>15000) over the D2 receptor. In addition to their high
selectivity for the D3 receptor over the D2 receptor, compounds
15, 18, 21, 22, and 23 are also highly selective for the D3 re-
ceptor over the D1 receptor.
We next synthesized a series of compounds (24–35) in
which the amide group in compounds 11–23 is replaced by
a sulfonamide group (Table 3). These compounds retain high
affinities for the D3 receptor, but they are much less selective
than the most selective compounds with the amide group.
Compound 34 is the most selective compound among com-
pounds 24–35 containing a sulfo-
namide group, but has a selectiv-
ity of only 1052-fold for the D3
receptor over the D2 receptor ;
consequently, this series of com-
pounds was not pursued.
We next evaluated the human
liver microsomal stability for
compounds 20, 21, and 23,
three potent and highly selective
D3 ligands, in direct comparison
with compounds 2 and 3. The results are listed in Table 1. Our
data show that compounds 20, 21, and 23 all have t1/2>
60 min, indicating that the microsomal stability of these com-
pounds is indeed much improved over that of compounds 2
or 3.
We next evaluated compounds 15, 18, 21, 23, 33, and 34
for their functional activity at the human D3 receptor in a quin-
pirole-induced mitogenesis assay in hD3-transfected CHOp
cells. The results, presented in Table 4, show that all these com-
pounds behave as highly potent full D3 agonists.
Synthesis of designed compounds
The synthetic route to compounds 11–23 is shown in
Scheme 1. The commercially available cyclobutanone 5 was
treated with allylmagnesium bromide at 78 8C to give cis-al-
lylcyclobutanol 6. The stereochemistry of 6 was confirmed by
transformation into known compound 7, the stereochemistry
of which was determined by X-ray crystallographic analysis.[8]
Table 1. Human liver microsomal stability of representative com-
pounds.[a]
Compd Remaining in HLM [%] t1/2 [min]
0 min 5 min 10 min 15 min 30 min 60 min
2 100 84.6 72.2 63.6 41.1 20.1 26.1
3 100 79.2 49.9 34.9 11.7 2.1 9.48
20 100 97.7 94.1 94 85.5 76.7 >60
21 100 99.7 98.5 92.5 83 74.1 >60
23 100 96.6 99.2 99 90 65.5 >60
[a] Percentage compound remaining in human liver microsomes at indi-
cated time points; data represent single determinations.
Figure 2. Major biotransformation of compound 2 in human liver microsomes.
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Aldehyde 8 was obtained by oxi-
dation of 6 with NaIO4 and a cat-
alytic amount of OsO4. Pramipex-
ole (1) was allowed to react with
8 to give the key intermediate 9,
which, upon treatment with tri-
fluoroacetic acid, afforded amine
10. This amine was treated with
commercially available acid
chlorides in the presence of N,N-
diisopropylethylamine (DIPEA),
and the resulting crude amides
11–23 were purified by prepara-
tive HPLC.
The synthesis of the sulfona-
mide-containing compounds
24–35 is shown in Scheme 2.
Briefly, these compounds were
synthesized by reaction of the
intermediate amine 10 at room
temperature with the appropri-
ate sulfonyl chlorides in DIPEA
and dichloromethane with 40–
56% yield.
Conclusions
In summary, modifications of the
naphthyl group in our previously
reported D3 ligand 2 yielded
a series of new compounds with
high binding affinities for the D3
receptor and high selectivity
over the D1 and D2 receptors,
and significantly with improved
microsomal stability. Compound
23, for example, binds to the D3
receptor with a Ki value of
0.53 nm, shows a selectivity of
>25000 over the D1 and D2 re-
ceptors, and superior microso-
mal stability to that of com-
pound 2 in human liver micro-
somes. Compound 23 is a full
agonist to the human D3 recep-
tor in the quinpirole-induced mi-
togenesis assay and represents
a potent and highly selective D3
agonist.
Experimental Section
Chemistry
General : Solvents and reagents
were purchased and used without
further purification. Reactions were
Table 2. Binding affinities of original lead compound 2 and new compounds 11–23 at the D1-like, D2-like, and
D3 receptors in binding assays using rat brain preparations.
Ligand R Ki [nm]
[a–c] Selectivity
D3
[a] D2-like
[b] D1-like
[c] D2-like/D3 D1-like/D3
2 0.400.087 72545 1610167 1827 4025
11 0.740.038 2249 1970179 301 2662
12 0.620.068 7211 497002807 117 80161
13 0.580.062 10112 287002640 175 49482
14 1.60.19 24446 15113780 157 9751
15 0.460.06 170004092 536008380 36956 116521
16 1.90.087 26446 566002730 138 29789
17 0.890.17 36727 500004890 412 56180
18 0.430.06 69501095 282005308 16272 65581
19 1.00.094 15825 43500711 160 44500
20 0.700.055 2660461 428003279 3779 61143
21 0.760.036 97901500 642001760 12836 84474
22 0.960.10 146001280 192002550 15208 20000
23 0.530.07 158005910 150002920 29800 28300
[a] D3 receptor binding was determined using [
3H]7-OH-DPAT and membranes prepared from ventral striatum.
[b] D2-like receptor binding (D2, D3, and D4) was determined using [
3H]spiperone and striatal membranes. For
those compounds that produced a competition curve consistent with two-site inhibition, which is typical of
the behavior of agonists in this assay, the Ki value for the high-affinity component is reported. [c] D1-like recep-
tor binding (D1 and D5) was determined using [
3H]SCH23390 and striatal membranes. Data are the mean 
SEM of 3–6 independent determinations.
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monitored by thin-layer chromatography (TLC) carried out on
250 mm silica gel plates (E. Merck, 60 F254) using UV light as visualiz-
ing agent. Silica gel 60 (E. Merck, particle size: 15–40 mm) was used
for flash column chromatography. NMR spectra were recorded on
a Bruker Avance 300 spectrometer (300 MHz). Chemical shifts (d)
are reported in ppm downfield relative to tetramethylsilane (TMS)
as an internal standard, with multi-
plicities reported in the standard
form. All final compounds have
purities >95%, as determined by
HPLC (UV detection at l 254 nm).
tert-Butyl (3-allyl-3-hydroxycyclo-
butyl)carbamate (6). Allylmagnesi-
um bromide solution (1m) in ether
(64.8 mL, 64.8 mmol) was added
dropwise to a solution of tert-butyl
(3-oxocyclobutyl)carbamate 29
(6.0 g, 32.4 mmol) in anhydrous
THF at 78 8C, and the reaction
mixture was stirred at 78 8C for
2 h. Then the mixture was allowed
to warm slowly to room tempera-
ture. The reaction was quenched
by slow addition of aqueous satu-
rated NH4Cl. The mixture was ex-
tracted with EtOAc (340 mL) and
organic layers were combined. The
organic solvents were removed
under vacuum, and the residue
was purified by column chroma-
tography (SiO2, hexanes/EtOAc 2:1)
to give 6 (5.0 g, 68%) as a colorless
oil. 1H NMR (CDCl3, 300 MHz): d=
5.90–5.70 (m, 1H), 5.25–5.10 (m,
2H), 4.70 (br, 1H), 3.80–3.70 (m,
1H), 2.35 (d, J=3.2 Hz, 2H), 2.20 (s,
1H), 2.00–1.80 (m, 2H), 1.44 ppm
(s, 9H).
N-(cis-3-Allyl-3-hydroxycyclobu-
tyl)-2-naphthamide (7). TFA (1 mL)
was added to a solution of 30
(500 mg, 2.20 mmol) in CH2Cl2
(5 mL) and the mixture was stirred
at room temperature for 12 h. Sol-
vent and TFA were removed under
vacuum and the residue was dis-
solved in CH2Cl2 (5 mL). DIPEA
(568 mg, 4.40 mmol) and 2-naph-
thoyl chloride (502 mg, 2.64 mmol)
were added and the mixture was
stirred at room temperature for
2 h. The reaction was quenched
with H2O and the pH was adjusted
to 9–10 by addition of aqueous
Na2CO3. The mixture was extracted
with CH2Cl2 (330 mL). The organ-
ic layer was separated, combined,
dried, and evaporated. The residue
was purified by chromatography
(SiO2, hexanes/EtOAc 1:1) to give 7
as a colorless solid (445 mg, 72%
over two steps). 1H NMR (CDCl3,
300 MHz): d=8.27 (s, 1H), 7.95–
7.75 (m, 4H), 7.65–7.50 (m, 2H), 6.51 (d, J=6.5 Hz, 1H), 6.00–5.80
(m, 1H), 5.30–5.20 (m, 2H), 4.45–4.27 (m, 1H), 2.80–2.70 (m, 2H),
2.43 (d, J=7.1 Hz, 2H), 2.36 (s, 1H), 2.25–2.15 ppm (m, 2H).
tert-Butyl (3-hydroxy-3-(2-oxoethyl)cyclobutyl)carbamate (8).
OsO4 (223 mg, 0.881 mmol) was added to a solution of 30 (2.0 g,
Table 3. Binding affinities of new compounds 24–35 at the D1-like, D2-like, and D3 receptors in binding assays
using rat brain preparation.[a]
Ligand R Ki [nm]
[a–c] Selectivity
D3
[a] D2-like
[b] D1-like
[c] D2-like/D3 D1-like/D3
24 1.90.17 8111 570002830 42 30000
25 2.30.22 17018 181093 75 800
26 1.60.16 1608.5 365002243 98 22812
27 1.60.090 10215 2610255 65 1631
28 0.590.057 28649 949007620 485 160847
29 2.50.15 714.8 680002300 28 27200
30 2.60.20 54279 459002490 205 17654
31 1.00.072 61968 1090002500 614 109000
32 1.20.091 11014 11700010170 91 97500
33 1.90.25 78936 1020005390 414 53684
34 2.30.25 2420118 419002764 1052 18217
35 3.10.26 577.4 760006810 19 24516
[a] D3 receptor binding was determined using [
3H]7-OH-DPAT and membranes prepared from ventral striatum.
[b] D2-like receptor binding (D2, D3, and D4) was determined using [
3H]spiperone and striatal membranes. For
those compounds that produced a competition curve consistent with two-site inhibition, which is typical of
the behavior of agonists in this assay, the Ki value for the high-affinity component is reported. [c] D1-like recep-
tor binding (D1 and D5) was determined using [
3H]SCH23390 and striatal membranes. Data are the mean 
SEM of 3–6 independent determinations.
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8.81 mmol) in THF/H2O (80 mL, 1:1 ratio) at room temperature and
the mixture was stirred at room temperature for 30 min. Then,
NaIO4 (4.71 g, 22 mmol) was added and the mixture was stirred for
30 min. The mixture was extracted with EtOAc (340 mL) and or-
ganic layers were combined. Evaporation of organic solvents under
vacuum gave crude product 8 (1.2 g, crude yield 60%) as a pale-
yellow oil. This crude product was used directly for the next step
without further purification. Purification of this crude product by
silica gel column chromatography led to its decomposition.
tert-Butyl (3-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-
yl)(propyl)amino)ethyl)-3-hydroxycyclobutyl)carbamate (9). Com-
pound 8 (8.93 g, 39.0 mmol), acetic acid (3.51 g, 58.5 mmol) and
sodium triacetoxyborohydride (12.4 g, 58.5 mmol) were added to
a solution of pramipexole (8.3 g, 39.0 mmol) in CH2Cl2 (60 mL) and
the reaction mixture was stirred at room temperature for 6 h. The
reaction was quenched with H2O and the pH was adjusted to 9–10
by addition of aqueous Na2CO3 solution. The mixture was then ex-
tracted with CH2Cl2 (330 mL). The organic layers were separated,
combined, and evaporated. The residue was subjected
to chromatography (SiO2, EtOAc/MeOH 95:5) to give
compound 9 (4.5 g, 27% yield). 1H NMR (CDCl3,
300 MHz): d=4.90 (s, 2H), 4.77 (d, J=7.8 Hz, 1H), 3.80–
3.60 (m, 1H), 3.25–3.10 (m, 1H), 2.80–2.35 (m, 10H),
2.00–1.45 (m, 8H), 1.43 (s, 9H), 0.89 ppm (t, J=7.2 Hz,
3H).
3-Amino-1-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]-
thiazol-6-yl)(propyl)amino)ethyl)cyclobutanol (10). TFA
(5 mL) was added to a solution of 9 (4.5 g, 10.6 mmol) in
CH2Cl2 (30 mL) and the mixture was stirred at room tem-
perature for 12 h. Solvent and TFA were removed under vacuum.
H2O was added to the residue and pH was adjusted to 9–10 by ad-
dition of aqueous Na2CO3 solution. The mixture was extracted with
CH2Cl2 (330 mL). The organic layers were separated, combined,
dried, and evaporated. The residue was subjected to chromatogra-
phy (SiO2, CH2Cl2/MeOH 80:20) to give compound 10 as a colorless
oil (3.1 g, 90% yield). 1H NMR (CD3OD, 300 MHz): d=4.02–3.83 (m,
1H), 3.60–2.60 (m, 11H), 2.40–1.75 (m, 8H), 1.06 ppm (t, J=7.2 Hz,
3H).
General procedure for the synthesis of compounds 11–23. DIPEA
(52 mg, 0.4 mmol) and the appropriate acid chloride (0.24 mmol)
were added to a suspension of 10 (65 mg, 0.2 mmol) in CH2Cl2
(10 mL) and the mixture was stirred at room temperature for 2 h.
The reaction was quenched with H2O and pH was adjusted to 9–
10 by addition of aqueous Na2CO3. The mixture was extracted with
CH2Cl2 (330 mL). The organic layer was separated, combined,
dried, and evaporated. The residue was purified by preparative
HPLC to give the product. This procedure was used to prepare
compounds 11–23, as detailed below.
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)benzamide (11). Color-
less solid (47 mg, 55%). 1H NMR (CD3OD, 300 MHz): d=7.83 (d, J=
7.1 Hz, 2H), 7.60–7.40 (m, 3H), 4.20–3.90 (m, 2H), 3.60–2.60 (m,
10H), 2.40–1.80 (m, 8H), 1.08 ppm (t, J=7.3 Hz, 3H); 13C NMR
(CD3OD, 75 MHz): d=171.8, 170.0, 135.4, 134.6, 132.8, 129.6, 128.4,
112.9, 69.7, 60.0, 54.4, 44.1, 38.1, 34.4, 23.9, 23.4, 22.9, 19.8,
11.2 ppm; MS m/z 429 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-chlorobenzamide
(12). Colorless solid (42 mg, 45%). 1H NMR (CD3OD, 300 MHz): d=
7.50–7.37 (m, 4H), 4.18–3.82 (m, 2H), 3.60–2.60 (m, 10H), 2.40–1.70
Table 4. Functional agonist activity of representative D3 ligands in the
quinpirole-induced mitogenesis assay in hD3-transfected CHOp cells.
Ligand IC50 [nm]
[a] Stimulation [%][b]
15 2.00.49 100
18 2.00.34 100
21 182.7 100
23 191.5 100
33 174.4 100
34 264.1 100
[a] Data are the mean SEM of 3–6 independent determinations. [b] Rel-
ative to quinpirole as the standard agonist.
Scheme 1. Synthesis of compounds 11–23. Reagents and conditions : a) allylmagnesium bromide, THF, 78 8C, 4 h, 68%; b) 1. TFA, CH2Cl2, RT, 12 h, 2. 2-naph-
thoyl chloride, DIPEA, CH2Cl2, RT, 2 h, 72%; c) OsO4, NaIO4, THF/H2O, RT, 30 min, 60%; d) 8, NaBH(OAc)3, HOAc, CH2Cl2, 27%; e) TFA, CH2Cl2, RT, 12 h, 90%; f) ap-
propriate acid chlorides, DIPEA, CH2Cl2, RT, 2 h, 36–66%.
Scheme 2. Synthesis of compounds 24–35. Reagents and conditions : a) appropriate sulfo-
nyl chlorides, DIPEA, CH2Cl2, RT, 2 h, 40–56%.
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(m, 8H), 1.07 ppm (t, J=7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=
171.8, 169.6, 137.5, 134.4, 132.2, 131.9, 131.0, 129.8, 128.2, 112.9,
69.6, 60.0, 54.4, 44.0, 37.9, 34.3, 23.8, 23.3, 22.9, 19.8, 11.2 ppm; MS
m/z 463 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-chlorobenzamide
(13). Colorless solid (52 mg, 56%). 1H NMR (CD3OD, 300 MHz): d=
7.83–7.70 (m, 2H), 7.60–7.40 (m, 2H), 4.18–3.83 (m, 2H), 3.60–2.60
(m, 10H), 2.40–1.72 (m, 8H), 1.08 ppm (t, J=7.3 Hz, 3H); 13C NMR
(CD3OD, 75 MHz): d=171.8, 168.3, 137.4, 135.6, 134.5, 132.6, 131.2,
128.5, 126.8, 112.9, 69.7, 60.0, 54.5, 44.0, 38.2, 34.4, 23.9, 23.4, 22.9,
19.8, 11.2 ppm; MS m/z 463 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-chlorobenzamide
(14). Colorless solid (54 mg, 58%). 1H NMR (CD3OD, 300 MHz): d=
7.81 (d, J=8.6 Hz, 2H), 7.47 (d, J=8.6 Hz, 2H), 4.16–3.83 (m, 2H),
3.60–2.60 (m, 10H), 2.40–1.72 (m, 8H), 1.06 ppm (t, J=7.3 Hz, 3H);
13C NMR (CD3OD, 75 MHz): d=171.8, 168.7, 138.8, 134.4, 134.1,
130.1, 129.7, 112.9, 69.7, 60.0, 54.4, 44.0, 38.2, 34.4, 23.9, 23.4, 22.9,
19.8, 11.2 ppm; MS m/z 463 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-fluorobenzamide
(15). Colorless solid (40 mg, 45%). 1H NMR (CD3OD, 300 MHz): d=
7.81–7.77 (m, 1H), 7.67–7.65 (m, 1H), 7.42–7.30 (m, 2H), 4.25–4.08
(m, 2H), 3.55–2.83 (m, 10H), 2.46–1.96 (m, 8H), 1.19 ppm (t, J=
7.1 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.9, 166.7, 163.0 (d,
JFC=247.9 Hz), 134.5, 134.3 (d, JFC=8.6 Hz), 131.4 (d, JFC=
2.5 Hz), 125.8 (d, JFC=3.5 Hz), 124.5 (d, JFC=13.8 Hz), 117.5 (d,
JFC=22.7 Hz), 113.0, 69.8, 60.1, 54.58, 44.3, 38.1, 34.5, 24.0, 23.5,
23.0, 19.9, 11.2 ppm; MS m/z 447 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-fluorobenzamide
(16). Colorless solid (32 mg, 36%). 1H NMR (CD3OD, 300 MHz): d=
7.70–7.43 (m, 3H), 7.35–7.24 (m, 1H), 4.16–3.85 (m, 2H), 3.60–2.62
(m, 10H), 2.42–1.74 (m, 8H), 1.08 ppm (t, J=7.3 Hz, 3H); 13C NMR
(CD3OD, 75 MHz): d=171.8, 168.4, 164.1 (d, JFC=244.0 Hz), 137.8
(d, JFC=6.8 Hz), 134.4, 131.5 (d, JFC=7.9 Hz), 124.2 (d, JFC=
2.7 Hz), 119.5 (d, JFC=21.5 Hz), 115.3 (d, JFC=23.1 Hz), 112.9, 69.7,
60.0, 54.5, 44.0, 38.2, 34.4, 23.8, 23.3, 22.8, 19.8, 11.2 ppm; MS m/z
447 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-fluorobenzamide
(17). Colorless solid (59 mg, 66%). 1H NMR (CD3OD, 300 MHz): d=
7.90–7.80 (m, 2H), 7.18 (t, J=8.8 Hz, 2H), 4.16–3.83 (m, 2H), 3.60–
2.62 (m, 10H), 2.42–1.70 (m, 8H), 1.06 ppm (t, J=7.3 Hz, 3H);
13C NMR (CD3OD, 75 MHz): d=171.8, 168.8, 166.2 (d, JFC=
248.8 Hz), 134.3, 131.8 (d, JFC=2.9 Hz), 131.0 (d, JFC=9.0 Hz),
116.4 (d, JFC=22.1 Hz), 112.9, 69.7, 60.0, 54.4, 44.1, 38.1, 34.4, 23.8,
23.3, 22.8, 19.8, 11.2 ppm; MS m/z 447 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-chloro-4-fluoroben-
zamide (18). Colorless solid (39 mg, 40%). 1H NMR (CD3OD,
300 MHz): d=8.01–7.98 (m, 1H), 7.86–7.81 (m, 1H), 7.40–7.34 (m,
1H), 4.30–3.80 (m, 2H), 3.65–2.63 (m, 10H), 2.46–1.76 (m, 8H),
1.08 ppm (t, J=7.4 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=170.4,
166.0, 161.6 (d, JFC=251.3 Hz), 133.2, 131.5 (d, JFC=3.7 Hz), 129.8,
127.9 (d, JFC=8.2 Hz), 120.8 (d, JFC=18.2 Hz), 116.6 (d, JFC=
21.8 Hz), 111.5, 68.3, 58.6, 53.0, 42.6, 36.9, 33.0, 22.5, 22.0, 21.5,
18.4, 9.8 ppm; MS m/z 481 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-methoxybenzamide
(19). Colorless solid (50 mg, 54%). 1H NMR (CD3OD, 300 MHz): d=
7.84 (dd, J=1.7, 7.7 Hz, 2H), 7.53–7.45 (m, 1H), 7.14 (d, J=8.3 Hz,
1H), 7.08–7.00 (m, 1H), 4.18–3.83 (m, 2H), 3.92 (s, 3H), 3.60–2.60
(m, 10H), 2.40–1.70 (m, 8H), 1.06 ppm (t, J=7.3 Hz, 3H); 13C NMR
(CD3OD, 75 MHz): d=171.8, 167.8, 159.0, 134.3, 134.2, 131.8, 123.0,
121.9, 112.9, 69.9, 60.0, 56.5, 54.4, 44.5, 37.7, 34.4, 23.8, 23.3, 22.8,
19.8, 11.2 ppm; MS m/z 459 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-methoxybenzamide
(20). Colorless solid (41 mg, 45%). 1H NMR (CD3OD, 300 MHz): d=
7.80 (d, J=8.8 Hz, 2H), 6.97 (d, J=8.8 Hz, 2H), 4.18–3.85 (m, 2H),
3.84 (s, 3H), 3.60–2.60 (m, 10H), 2.40–1.70 (m, 8H), 1.05 ppm (t, J=
7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.8, 169.5, 164.0,
134.3, 130.2, 127.4, 114.7, 112.9, 69.7, 59.9, 55.9, 54.4, 44.1, 38.0,
34.4, 23.8, 23.3, 22.8, 19.8, 11.2 ppm; MS m/z 459 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-methoxybenzamide
(21). Colorless solid (53 mg, 58%). 1H NMR (CD3OD, 300 MHz): d=
7.42–7.30 (m, 3H), 7.13–7.05 (m, 1H), 4.18–3.81 (m, 2H), 3.84 (s,
3H), 3.60–2.60 (m, 10H), 2.40–1.70 (m, 8H), 1.06 ppm (t, J=7.3 Hz,
3H); 13C NMR (CD3OD, 75 MHz): d=171.8, 169.8, 161.2, 136.8,
134.3, 130.7, 120.5, 118.5, 113.7, 112.9, 69.7, 60.0, 55.9, 54.4, 44.05,
38.1, 34.4, 23.8, 23.3, 22.8, 19.8, 11.2 ppm; MS m/z 459 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-(5-methyl-1,2,4-ox-
adiazol-3-yl)benzamide (22). Colorless solid (46 mg, 45%). 1H NMR
(CD3OD, 300 MHz): d=8.17 (d, J=8.1 Hz, 2H), 7.98 (d, J=8.1 Hz,
2H), 4.20–3.85 (m, 2H), 3.60–2.70 (m, 10H), 2.69 (s, 3H), 2.45–1.82
(m, 8H), 1.10 ppm (t, J=7.5 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=
179.2, 171.8, 169.1, 168.9, 137.9, 134.7, 131.1, 129.1, 128.4, 113.0,
69.7, 60.1, 54.5, 44.1, 38.3, 34.4, 23.9, 23.4, 23.0, 19.9, 12.1,
11.2 ppm; MS m/z 511 [M+H]+ .
N-(cis-3-(2-(((S)-2-amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-(5-methyl-1,2,4-ox-
adiazol-3-yl)benzamide (23). Colorless solid (58 mg, 57%). 1H NMR
(CD3OD, 300 MHz): d=8.52 (m, 1H), 8.23–8.21 (m, 1H), 8.02–7.99
(m, 1H), 7.67–7.62 (m, 1H), 4.25–3.85 (m, 2H), 3.60–2.70 (m, 10H),
2.69 (s, 3H), 2.45–1.75 (m, 8H), 1.09 ppm (t, J=7.3 Hz, 3H);
13C NMR (CD3OD, 75 MHz): d=179.1, 171.8, 169.1, 169.0, 136.4,
134.6, 131.2, 131.0, 130.4, 128.6, 127.3, 112.9, 69.8, 60.0, 54.5, 44.1,
38.3, 34.5, 23.9, 23.4, 22.9, 19.8, 12.1, 11.2 ppm; MS m/z 511 [M+
H]+ .
General procedure for the synthesis of compounds 24–35. DIPEA
(52 mg, 0.4 mmol) and appropriate sulfonyl chlorides (0.24 mmol)
were added to a suspension of 10 (65 mg, 0.2 mmol) in CH2Cl2
(10 mL) and the mixture was stirred at room temperature for 2 h.
The reaction was quenched with H2O and pH was adjusted to 9–
10 by addition of aqueous Na2CO3. The mixture was extracted with
CH2Cl2 (330 mL). The organic lawyer was separated, combined,
dried, and evaporated. The residue was purified by preparative
HPLC to give the product. This procedure was used to prepare
compounds 24–35 as described below.
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)benzenesulfonamide
(24). Colorless solid (37 mg, 40%). 1H NMR (CD3OD, 300 MHz): d=
7.86 (d, J=6.9 Hz, 2H), 7.80–7.50 (m, 3H), 4.00–3.80 (m, 1H), 3.50–
2.65 (m, 9H), 2.50–1.60 (m, 10H), 1.03 ppm (t, J=7.3 Hz, 3H);
13C NMR (CD3OD, 75 MHz): d=171.7, 142.4, 134.5, 133.7, 130.3,
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128.0, 112.9, 69.3, 59.9, 54.3, 44.8, 40.5, 34.2, 23.8, 23.3, 22.9, 19.7,
11.1 ppm; MS m/z 465 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-methoxybenzene-
sulfonamide (25). Colorless solid (42 mg, 42%). 1H NMR (CD3OD,
300 MHz): d=7.80 (d, J=8.3 Hz, 1H), 7.62 (t, J=7.6 Hz, 1H), 7.21
(d, J=8.3 Hz, 1H), 7.08 (t, J=7.6 Hz, 1H), 3.96 (s, 3H), 3.94–3.80 (m,
1H), 3.40–2.60 (m, 9H), 2.35–1.65 (m, 10H), 1.02 ppm (t, J=7.3 Hz,
3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 158.1, 136.0, 134.3,
131.1, 129.3, 121.4, 113.6, 112.9, 69.3, 59.9, 56.6, 54.3, 44.5, 40.7,
34.1, 23.7, 23.3, 22.8, 19.7, 11.1 ppm; MS m/z 495 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-methoxybenzene-
sulfonamide (26). Colorless solid (49 mg, 50%). 1H NMR (CD3OD,
300 MHz): d=7.50–7.13 (m, 4H), 3.95–3.80 (m, 1H), 3.83 (s, 3H),
3.50–2.60 (m, 9H), 2.42–1.62 (m, 10H), 1.03 ppm (t, J=7.3 Hz, 3H);
13C NMR (CD3OD, 75 MHz): d=171.7, 161.5, 143.6, 134.4, 131.4,
120.0, 119.4, 113.2, 112.9, 69.3, 59.9, 56.2, 44.7, 40.5, 34.2, 23.7, 23.3,
22.8, 19.7, 11.1 ppm; MS m/z 495 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-methoxybenzene-
sulfonamide (27). Colorless solid (44 mg, 44%). 1H NMR (CD3OD,
300 MHz): d=7.78 (d, J=8.9 Hz, 2H), 7.07 (d, J=8.9 Hz, 2H), 3.97–
3.83 (m, 1H), 3.85 (s, 3H), 3.42–2.60 (m, 9H), 2.42–1.65 (m, 10H),
1.03 ppm (t, J=7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.7,
164.5, 134.4, 133.8, 130.2, 115.3, 112.9, 69.4, 59.9, 56.2, 44.8, 40.5,
34.2, 23.7, 23.3, 22.8, 19.7, 11.1 ppm; MS m/z 495 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-chlorobenzenesul-
fonamide (28). Colorless solid (56 mg, 56%). 1H NMR (CD3OD,
300 MHz): d=8.04 (d, J=7.8 Hz, 1H), 7.62–7.42 (m, 3H), 3.98–3.80
(m, 1H), 3.48–2.63 (m, 9H), 2.40–1.70 (m, 10H), 1.02 ppm (t, J=
7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 139.5, 135.1,
134.2, 132.9, 132.8, 132.2, 128.5, 112.9, 69.2, 59.9, 54.3, 44.6, 40.5,
34.1, 23.7, 23.2, 22.8, 19.7, 11.1 ppm; MS m/z 499 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-chlorobenzenesul-
fonamide (29). Colorless solid (47 mg, 47%). 1H NMR (CD3OD,
300 MHz): d=7.81–7.66 (m, 2H), 7.64–7.43 (m, 2H), 3.95–3.78 (m,
1H), 3.40–2.60 (m, 9H), 2.44–1.65 (m, 10H), 1.01 ppm (t, J=7.3 Hz,
3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 144.5, 136.1, 134.2,
133.7, 132.0, 127.9, 126.4, 112.9, 69.3, 59.9, 54.4, 44.8, 40.5, 34.2,
23.8, 23.3, 22.8, 19.7, 11.1 ppm; MS m/z 499 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-4-chlorobenzenesul-
fonamide (30). Colorless solid (49 mg, 49%). 1H NMR (CD3OD,
300 MHz): d=7.84 (d, J=8.6 Hz, 2H), 7.58 (d, J=8.6 Hz, 2H), 3.95–
3.80 (m, 1H), 3.50–2.65 (m, 9H), 2.49–1.70 (m, 10H), 1.02 ppm (t,
J=7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 141.3, 139.9,
134.2, 130.5, 129.8, 112.9, 69.3, 59.9, 54.3, 44.7, 40.5, 34.1, 23.7,
23.3, 22.8, 19.8, 11.1 ppm; MS m/z 499 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-2-fluorobenzenesul-
fonamide (31). Colorless solid (39 mg, 40%). 1H NMR (CD3OD,
300 MHz): d=7.87–7.80 (m, 1H), 7.70–7.60 (m, 1H), 7.40–7.25 (m,
2H), 3.95–3.80 (m, 1H), 3.52–2.63 (m, 9H), 2.45–1.70 (m, 10H),
1.01 ppm (t, J=7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.7,
160.3 (d, JFC=252.3 Hz), 136.4 (d, JFC=8.4 Hz), 134.4, 131.2, 130.2
(d, JFC=13.7 Hz), 125.8 (d, JFC=3.8 Hz), 118.1 (d, JFC=24.2 Hz),
112.9, 69.2, 59.9, 54.3, 44.7, 40.5, 34.1, 23.8, 23.3, 22.8, 19.7,
11.1 ppm; MS m/z 483 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-fluorobenzenesul-
fonamide (32). Colorless solid (42 mg, 43%). 1H NMR (CD3OD,
300 MHz): d=7.70–7.50 (m, 3H), 7.42–7.30 (m, 1H), 3.95–3.82 (m,
1H), 3.50–2.60 (m, 9H), 2.45–1.70 (m, 10H), 1.01 ppm (t, J=7.3 Hz,
3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 163.9 (d, JFC=147.9 Hz),
144.7 (d, JFC=6.5 Hz), 134.2, 132.5 (d, JFC=7.9 Hz), 124.0, 120.7
(d, JFC=21.4 Hz), 115.0 (d, JFC=24.5 Hz), 112.9, 69.3, 59.9, 54.3,
44.7, 40.5, 34.2, 23.7, 23.3, 22.8, 19.7, 11.1 ppm; MS m/z 483 [M+
H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)-ethyl)-3-hydroxycyclobutyl)-4-fluorobenzenesul-
fonamide (33). Colorless solid (49 mg, 51%). 1H NMR (CD3OD,
300 MHz): d=7.89 (dd, J=5.1, 8.9 Hz, 2H), 7.29 (dd, J=8.9, 8.9 Hz,
2H), 3.95–3.80 (m, 1H), 3.48–2.65 (m, 9H), 2.49–1.70 (m, 10H),
1.01 ppm (t, J=7.3 Hz, 3H); 13C NMR (CD3OD, 75 MHz): d=171.7,
166.4 (d, JFC=250.8 Hz), 138.7 (d, JFC=3.2 Hz), 134.4, 130.9 (d,
JFC=9.3 Hz), 117.3 (d, JFC=22.8 Hz), 112.9, 69.3, 60.0, 59.9, 54.4,
44.7, 40.5, 34.2, 23.8, 23.3, 22.8, 19.7, 11.1 ppm; MS m/z 483 [M+
H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3-chloro-4-fluoroben-
zenesulfonamide (34). Colorless solid (50 mg, 48%). 1H NMR
(CD3OD, 300 MHz): d=7.98 (dd, J=2.2, 6.8 Hz, 1H), 7.83–7.75 (m,
1H), 7.47 (t, J=8.8 Hz, 1H), 3.96–3.80 (m, 1H), 3.50–2.63 (m, 9H),
2.45–1.70 (m, 10H), 1.03 ppm (t, J=7.3 Hz, 3H); 13C NMR (CD3OD,
75 MHz): d=171.7, 161.7 (d, JFC=254.7 Hz), 140.1 (d, JFC=3.8 Hz),
134.5, 130.8, 129.1 (d, JFC=8.6 Hz), 122.9 (d, JFC=18.8 Hz), 118.7
(d, JFC=22.4 Hz), 112.9, 69.3, 59.9, 54.32, 44.7, 40.5, 34.2, 23.8,
23.3, 22.9, 19.7, 11.1 ppm; MS m/z 517 [M+H]+ .
N-(cis-3-(2-(((S)-2-Amino-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)-
(propyl)amino)ethyl)-3-hydroxycyclobutyl)-3,4-difluorobenzene-
sulfonamide (35). Colorless solid (40 mg, 40%). 1H NMR (CD3OD,
300 MHz): d=7.80–7.70 (m, 2H), 7.55–7.43 (m, 1H), 3.95–3.80 (m,
1H), 3.50–2.60 (m, 9H), 2.45–1.70 (m, 10H), 1.02 ppm (t, J=7.3 Hz,
3H); 13C NMR (CD3OD, 75 MHz): d=171.7, 154.4 (dd, JFC=12.5,
212.0 Hz), 151.1 (dd, JFC=12.5, 209.8 Hz), 139.8 (t, JFC=4.2 Hz),
134.3, 125.6 (dd, JFC=3.9, 7.6 Hz), 119.5 (d, JFC=18.5 Hz), 117.8 (d,
JFC=19.9 Hz), 112.9, 69.3, 60.3, 54.3, 44.7, 40.5, 34.2, 23.8, 23.3,
22.8, 19.7, 11.1 ppm; MS m/z 501 [M+H]+ .
Biology
In vitro dopamine receptor binding assays. The binding affinities of
all synthetic compounds were determined at the D1-like, D2-like,
and D3 receptors in membranes prepared from the brains of adult
male Sprague–Dawley rats (Pel-Freez Biologicals, Rogers, AR, USA).
For these assays, all compounds were dissolved in 100% EtOH at
a concentration of 5 mm.
[3H]R-(+)-7-OH-DPAT binding assays. [3H]R-(+)-7-OH-DPAT binding
assays for the D3 dopamine receptors were performed as described
previously under conditions that yield selective labeling of the D3
receptor.[10] Rat ventral striatal (nucleus accumbens and olfactory
tubercles) membrane was prepared in an assay buffer (50 mm Tris,
1 mm EDTA; pH 7.4 at 23 8C) to yield a final concentration of 10 mg
original wet weight (o.w.w.) per mL. Membranes were incubated
with [3H]R-(+)-7-OH-DPAT (0.15 nm, SA=163 Cimmol1, GE Health-
care, or SA=143 Cimmol1, PerkinElmer) and various concentra-
tions of the test compounds (1010 to 104m). Nonspecific binding
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was defined by 1 mm spiperone. Assay tubes were incubated at
23 8C for 90 min. Reactions were terminated by rapid vacuum filtra-
tion. Data were analyzed using SigmaPlot 8.0.2, with KD=0.15 nm
for [3H]7-OH-DPAT.[10] Ki values are expressed as the mean SEM of
3–6 independent determinations.
[3H]Spiperone binding assays. [3H]Spiperone binding assays for D2-
like receptors were performed as described previously[11] for [3H]7-
OH-DPAT with the following exception. Assays were performed
with membranes prepared from rat caudate-putamen, which ex-
presses D2 receptors at high density, but with very low levels of D3
receptors, and the final membrane homogenate concentration was
1.5 mg o.w.w. per mL. The assay buffer, 50 mm Tris·HCl, 5 mm KCl,
2 mm MgCl2, and 2 mm CaCl2, pH 7.4 at 23 8C, was used to opti-
mize conditions for agonist binding.[12] The concentration of
[3H]spiperone (24 Cimmol1, SA=105 mmol, GE Healthcare; SA=
60, American Radiolabeled Chemicals; or SA=83.4, PerkinElmer)
was 0.2 nm, and the incubation time was 90 min at 23 8C. Nonspe-
cific binding was determined in the presence of 1 mm (+)-butacla-
mol. Ki values were calculated from the experimentally determined
KD value for [
3H]spiperone of 0.4 nm. For those compounds that
produced a competition curve consistent with two-site inhibition,
which is consistent with the behavior of agonists in this assay, the
Ki value for the high-affinity component is reported.
[3H]SCH23390 binding assays. [3H]SCH23390 (7-chloro-3-methyl-1-
phenyl-1,2,4,5-tetrahydro-3-benxazepin-8-ol) binding assays for D1-
like dopamine receptors were performed as described previously[13]
for [3H]spiperone binding, except the concentration of
[3H]SCH23390 (SA=73 Cimmol1, GE Healthcare or SA=
60 Cimmol1, Americal Radiolabeled Chemicals) used was 0.3 nm.
Ki values were calculated from the KD value for [
3H]SCH23390 of
0.3 nm.
DA D3 mitogenesis functional assays. CHOp-D3 cells were main-
tained in alpha-MEM with 10% fetal bovine serum (FBS, Atlas Bio-
logicals), 0.05% penicillin/streptomycin, and 400 mgmL1 of G418.
To measure D3 stimulation of mitogenesis (agonist assay) or inhibi-
tion of quinpirole stimulation of mitogenesis (antagonist assay),
CHOp-D3 cells were seeded in a 96-well plate at a concentration of
5000 cells per well. The cells were incubated at 37 8C in alpha-MEM
with 10% FBS. After 48–72 h, the cells were rinsed twice with
serum-free alpha-MEM then incubated for 24 h at 37 8C. Serial dilu-
tions of test compounds were made by the Biomek robotics
system in serum-free alpha-MEM. In the functional assay for ago-
nists, the medium was removed and replaced with 100 mL of a solu-
tion of the test compound in serum-free alpha-MEM. In the antag-
onist assay, the serial dilution of the putative antagonist test com-
pound was added in 90 mL of solution (1.1 of final concentration),
and 300 nm quinpirole (30 nm final) was added in 10 mL of the so-
lution. After a further 16 h incubation at 37 8C, 0.25 mCi of
[3H]thymidine in alpha-MEM supplemented with 10% FBS was
added to each well, and the plates were further incubated for 2 h
at 37 8C. The cells were trypsinized by addition of 10 trypsin solu-
tion (1% trypsin in calcium-/magnesium-free phosphate-buffered
saline [PBS]) and the plates were filtered and counted. Quinpirole
was assayed daily as an internal control, and dopamine was includ-
ed for comparative purposes.
Data analysis : For functional assays, GraphPad Prism 6 was used to
calculate either EC50 (agonists) or IC50 (antagonists) values using
data expressed as pg cAMP for adenylate cyclase activity and per-
cent quinpirole stimulation for mitogenesis.
Human liver microsomal stability assays. Each test compound
(1 mm) was metabolized at 37 8C by incubating the test compound
with 0.5 mgmL1 human liver microsomes and 1 mm NADPH co-
factor in a total volume of 400 mL of 100 mm potassium phosphate
buffer (pH 7.4 containing 3.3 mm MgCl2). The reactions were
stopped at 0, 5, 10, 15, 30, and 60 min, by adding threefold the
volume of CH3CN containing 100 nm of internal standard. The col-
lected fractions were centrifuged for 10 min at 21130 g to collect
the supernatant for LC–MS/MS analyses, from which the amount of
parent compound remaining was determined. The natural loga-
rithm of the amount of parent compound remaining was plotted
against time to calculate the rate of disappearance and half-life of
the tested compounds. Hydrolysis of 2, 3, 20, 21, and 23 in human
liver microsomes and a PBS-only solution was monitored under
similar conditions. Each compound (1 mm) was incubated with
0.5 mgmL1 human liver microsomes in PBS solution or with PBS
only for 60 min. No change in the concentration of three com-
pounds at 60 min relative to that at time zero suggests little hy-
drolysis had occurred for the three compounds in PBS solution
with or without human liver microsomes.
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